195 related articles for article (PubMed ID: 29663340)
1. Molecular signatures in hepatocellular carcinoma: A step toward rationally designed cancer therapy.
Erstad DJ; Fuchs BC; Tanabe KK
Cancer; 2018 Aug; 124(15):3084-3104. PubMed ID: 29663340
[TBL] [Abstract][Full Text] [Related]
2. m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in hepatocellular carcinoma.
Huang X; Qiu Z; Li L; Chen B; Huang P
Aging (Albany NY); 2021 Aug; 13(16):20698-20715. PubMed ID: 34461607
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive molecular and immunological characterization of hepatocellular carcinoma.
Shimada S; Mogushi K; Akiyama Y; Furuyama T; Watanabe S; Ogura T; Ogawa K; Ono H; Mitsunori Y; Ban D; Kudo A; Arii S; Tanabe M; Wands JR; Tanaka S
EBioMedicine; 2019 Feb; 40():457-470. PubMed ID: 30598371
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint therapy in liver cancer.
Xu F; Jin T; Zhu Y; Dai C
J Exp Clin Cancer Res; 2018 May; 37(1):110. PubMed ID: 29843754
[TBL] [Abstract][Full Text] [Related]
5. An immune-related gene signature for predicting survival and immunotherapy efficacy in hepatocellular carcinoma.
Dai Y; Qiang W; Lin K; Gui Y; Lan X; Wang D
Cancer Immunol Immunother; 2021 Apr; 70(4):967-979. PubMed ID: 33089373
[TBL] [Abstract][Full Text] [Related]
6. A novel hypoxia gene signature indicates prognosis and immune microenvironments characters in patients with hepatocellular carcinoma.
Zhang Q; Qiao L; Liao J; Liu Q; Liu P; Liu L
J Cell Mol Med; 2021 Apr; 25(8):3772-3784. PubMed ID: 33616276
[TBL] [Abstract][Full Text] [Related]
7. A signature of 33 immune-related gene pairs predicts clinical outcome in hepatocellular carcinoma.
Sun XY; Yu SZ; Zhang HP; Li J; Guo WZ; Zhang SJ
Cancer Med; 2020 Apr; 9(8):2868-2878. PubMed ID: 32068352
[TBL] [Abstract][Full Text] [Related]
8. Integrating transcriptomes and somatic mutations to identify RNA methylation regulators as a prognostic marker in hepatocellular carcinoma.
Yan Y; Luo YH; Zheng DF; Mu T; Wu ZJ
Hepatobiliary Pancreat Dis Int; 2021 Feb; 20(1):34-45. PubMed ID: 32563589
[TBL] [Abstract][Full Text] [Related]
9. Molecular subtypes, prognostic and immunotherapeutic relevant gene signatures mediated by DNA methylation regulators in hepatocellular carcinoma.
Shi R; Zhao H; Zhao S; Yuan H
Aging (Albany NY); 2022 Jun; 14(12):5271-5291. PubMed ID: 35771147
[TBL] [Abstract][Full Text] [Related]
10. Multi-omic analyses of hepatocellular carcinoma to determine immunological characteristics and key nodes in gene-expression network.
Wang Z; Zhang S
Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34212175
[TBL] [Abstract][Full Text] [Related]
11. TCGA and ESTIMATE data mining to identify potential prognostic biomarkers in HCC patients.
He G; Fu S; Li Y; Li T; Mei P; Feng L; Cai L; Cheng Y; Zhou C; Tang Y; Huang W; Liu H; Cen B; Pan M; Gao Y
Aging (Albany NY); 2020 Nov; 12(21):21544-21558. PubMed ID: 33177245
[TBL] [Abstract][Full Text] [Related]
12. Integrative analysis of DNA methylation and gene expression reveals distinct hepatocellular carcinoma subtypes with therapeutic implications.
Huang X; Yang C; Wang J; Sun T; Xiong H
Aging (Albany NY); 2020 Mar; 12(6):4970-4995. PubMed ID: 32201399
[TBL] [Abstract][Full Text] [Related]
13. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulatory TGF-β Signaling in Hepatocellular Carcinoma.
Chen J; Gingold JA; Su X
Trends Mol Med; 2019 Nov; 25(11):1010-1023. PubMed ID: 31353124
[TBL] [Abstract][Full Text] [Related]
15. N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma.
Cai J; Zhou M; Xu J
World J Surg Oncol; 2021 Aug; 19(1):241. PubMed ID: 34389000
[TBL] [Abstract][Full Text] [Related]
16. Hepatocellular carcinoma associated microRNA expression signature: integrated bioinformatics analysis, experimental validation and clinical significance.
Shi KQ; Lin Z; Chen XJ; Song M; Wang YQ; Cai YJ; Yang NB; Zheng MH; Dong JZ; Zhang L; Chen YP
Oncotarget; 2015 Sep; 6(28):25093-108. PubMed ID: 26231037
[TBL] [Abstract][Full Text] [Related]
17. Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma.
Gu JX; Zhang X; Miao RC; Xiang XH; Fu YN; Zhang JY; Liu C; Qu K
World J Gastroenterol; 2019 Jan; 25(2):220-232. PubMed ID: 30670911
[TBL] [Abstract][Full Text] [Related]
18. A novel microRNAs expression signature for hepatocellular carcinoma diagnosis and prognosis.
Lu M; Kong X; Wang H; Huang G; Ye C; He Z
Oncotarget; 2017 Jan; 8(5):8775-8784. PubMed ID: 28060739
[TBL] [Abstract][Full Text] [Related]
19. Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data.
Liu S; Tang Q; Huang J; Zhan M; Zhao W; Yang X; Li Y; Qiu L; Zhang F; Lu L; He X
Aging (Albany NY); 2021 Apr; 13(8):11257-11280. PubMed ID: 33820866
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma.
Dai X; Guo Y; Hu Y; Bao X; Zhu X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Fang W
Theranostics; 2021; 11(7):3489-3501. PubMed ID: 33537099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
